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Recently, there has been an increasing interest in immunomodulatory effects of vitamin D. Several 
studies have suggested detrimental effects of insufficient 25-hydroxyvitamin D (25(OH)D) levels on 
the innate and acquired immune system which may contribute to the development of infections, and 
atopic and allergic conditions [1-4] . Children as well as pregnant and lactating women have been 
identified as groups with a high risk of 25(OH)D insufficiency [5]. Low maternal serum 25(OH)D levels 
in pregnancy may contribute to increased risk of offspring infections and atopic outcomes.  Previous 
studies demonstrate inconsistency regarding relationships between maternal vitamin D intake, 
serum 25(OH)D levels and umbilical cord 25(OH)D levels with these outcomes in offspring [6-10]. We 
aimed to explore relationships between maternal serum 25(OH)D levels during late pregnancy and 
parent-reported respiratory tract symptoms and doctor-diagnosed lower respiratory tract infections 
(LRTI) in early childhood in a large cohort study . 
The study sample consisted of 2025 mother-child pairs from the Southampton Women’s Survey with 
maternal serum 25(OH)D measurement at 34 weeks’ gestation (Diasorin RIA, Diasorin, Stillwater, US) 
[11]. Follow-up was at children’s age 6 months (n=2026), 12 months (n=1946) and 2 years (n=1876). 
Parents were asked whether the child had suffered from any of the following since the last visit: one 
or more episodes of chest wheezing/whistling, waking at night coughing three or more nights in a 
row (prolonged cough), one or more episodes of croup or a croupy cough, bouts of vomiting or 
diarrhoea lasting 2 days or longer, or a doctor-diagnosed chest infection, bronchitis, bronchiolitis, 
pneumonia and/or ear infection. Chest infection, bronchitis, bronchiolitis and pneumonia were 
combined into one variable labelled “lower respiratory tract infection” (LRTI). Binary variables were 
created for each outcome. Relative risks were calculated by Poisson regression with robust variance 
with serum 25(OH)D>75 nmol/l as reference category [12].  All analyses were adjusted for child’s sex, 
birthweight and gestational age, and for maternal age at childbirth, educational level,  pre-pregnancy 
BMI, parity, ethnicity, smoking in pregnancy, and breast feeding duration. The study was approved by 
the Southampton and South West Hampshire Research Ethics Committee (276/97, 307/97, 089/99, 
06/Q1702/104). Parental consent was obtained before inclusion of participants.
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Median late-pregnancy serum 25(OH)D level was 59.0 [interquartile range 40.6-84.3] nmol/l. Lower 
late-pregnancy serum 25(OH)D levels were not associated with increased risk of parent-reported 
respiratory symptoms or infections in children aged 6 months, 12 months or 2 years. On the contrary, 
mothers with serum 25(OH)D levels below 50 nmol/l reported fewer respiratory symptoms and 
doctor-diagnosed LRTI in their children aged 0 to 6 months than those with serum 25(OH)D levels 
above75 nmol/l (Table 1). Additional adjustment for season of blood sampling (April to September 
versus October to March) did not alter our findings. 
Our results do not support an association between low late-pregnancy serum 25(OH)D levels and 
increased risk of parent-reported offspring respiratory symptoms and infections in early childhood. 
The positive associations between serum 25(OH)D levels and self-reported respiratory symptoms and 
LRTI at child’s age 0 to 6 months may be attributable to residual confounding. Thus, health conscious 
women have higher serum 25(OH)D levels and may be more prone to report their children’s 
symptoms and/or have an increased rate of consultation of a doctor at a similar level of symptoms. 
Other factors which may underlie discrepancies between studies include differences in measurement 
methods of  serum 25(OH)D levels and outcome prevalence, the nature of questions asked and 
reported behaviour [6-10].The strengths of this study are size and population-based nature. 
Limitations include the absence of objective outcomes regarding respiratory symptoms and 
infections and thus the presence of potential recall bias. In addition, awareness about study end-
points may have influenced medical behaviour of parents. Furthermore, 25(OH)D has a half-life of a 
few weeks, and we did not have 25(OH)D in early pregnancy, or postnatally in the offspring. Thus, 
mediation through 25(OH)D at other times in development remains a possibility, and clearly these 
observational data do not allow causality to be determined. Finally, wheezing may be a symptom of 
airway inflammation of either allergic or infectious cause and does not discriminate between these 
aetiologies. Randomized controlled trials are essential to clarify the role of vitamin D in pregnancy in 
relation to childhood respiratory symptoms and infections. 
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Table 1.Relative risks (95% CI) for self-reported respiratory symptoms and infections according to clinical serum 25(OH)D categories. 
25(OH)D category  <25 nmol/l 25-49 nmol/l 50-74 nmol/l >=75  nmol/l  
 N cases/N total RR (95% CI) RR (95% CI) RR (95% CI)  P-value 
0-6 months       
N (%) 2025 100 (4.9) 666 (32.9) 572 (28.2) 687 (33.9)  
Wheezing  525/2021 0.64 [0.44-0.95] 0.72 [0.61-0.87] 0.96 [0.81-1.15] reference 0.000 
Prolonged cough 319/2019  0.33 [0.16-0.69] 0.68 [0.53-0.88] 0.80 [0.62-1.02] reference 0.000 
Croupy cough 79/2024 0.13 [0.02-1.01] 0.27 [0.14-0.53] 0.68 [0.41-1.12] reference 0.000 
Diagnosed LRTI 288/2021 0.45 [0.24-0.84] 0.63 [0.49-0.81] 0.76 [0.58-0.99] reference 0.000 
Diagnosed ear infection 123/2024 0.83 [0.41-1.69] 0.64 [0.40-1.01] 0.93 [0.61-1.93] reference 0.142 
Diarrhoea 363/2024 0.99 [0.65-1.50] 0.93 [0.73-1.18] 1.05 [0.83-1.33] reference 0.484 
Vomiting 215/2024 1.04 [0.60-1.81] 0.86 [0.63-1.18] 0.98 [0.71-1.35] reference 0.733 
6-12 months       
N (%) 1946 94 (4.8) 628 (32.3) 552 (28.4) 672 (34.5)  
Wheezing  601/1946 1.10 [0.80-1.52] 1.21 [1.03-1.43] 1.17 [0.98-1.39] reference 0.163 
Prolonged cough 450/1945 1.09 [0.73-1.62] 1.16 [0.95-1.42] 1.09 [0.89-1.35] reference 0.196 
Croupy cough 142/1946 1.62 [0.86-3.04] 0.92 [0.62-1.36] 0.87 [0.58-1.32] reference 0.773 
Diagnosed LRTI 368/1946 1.11 [0.72-1.71] 1.22 [0.97-1.54] 1.12 [0.87-1.42] reference 0.155 
Diagnosed ear infection 386/1945 1.29 [0.87-1.92] 1.13 [0.90-1.42] 1.18 [0.93-1.48] reference 0.118 
Diarrhoea 691/1944 0.91 [0.67-1.25] 0.96 [0.83-1.12] 1.00 [0.86-1.16] reference 0.670 
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Vomiting 415/1944 1.26 [0.85-1.88] 1.18 [0.96-1.45] 0.96 [0.76-1.20] reference 0.046 
12-24 months       
N (%) 1876 95 (5.1) 601 (32.0) 537 (28.6) 643 (34.3)  
Wheezing  484/1876 0.85 [0.58-1.25] 1.01 [0.84-1.22] 0.92 [0.75-1.12] reference 0.991 
Prolonged cough 441/1875 0.82 [0.52-1.29] 1.19 [0.97-1.45] 1.07 [0.86-1.33] reference 0.328 
Croupy cough 210/1876 0.79 [0.42-1.48] 0.79 [0.58-1.08] 0.76 [0.55-1.05] reference 0.288 
Diagnosed LRTI 382/1875 0.69 [0.41-1.14] 0.98 [0.79-1.22] 0.92 [0.73-1.16] reference 0.929 
Diagnosed ear infection 506/1875 1.07 [0.77-1.50] 0.95 [0.78-1.14] 1.04 [0.86-1.25] reference 0.857 
Diarrhoea 671/1875 1.23 [0.95-1.57] 1.01 [0.87-1.18] 0.96 [0.82-1.13] reference 0.680 
Vomiting 467/1875 1.13 [0.79-1.61] 1.07 [0.88-1.30] 0.98 [0.80-1.20] reference 0.636 
P-values were derived from Poisson regression analyses with the log-transformed 25(OH)D levels as continuous variable. 
All analyses are adjusted for child’s sex, birthweight and gestational age, and for maternal age at childbirth, educational level, pre-pregnancy BMI, parity, 
ethnicity, smoking in pregnancy, and duration of breast feeding.
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Appendix online supplement   
Table. Characteristics of the mothers and children studied 
Vitamin D category <25 nmol/l 25-49 nmol/l 50-74 nmol/l >=75  nmol/l 
N 100 666 572 687 
Mothers     
Age at birth of child, years 30.5 (4.0) 30.2 (3.7) 30.5 (3.8) 30.6 (3.8) 
Pre-pregnancy BMI 24.3 (22.2-28.4) 24.4 (22.4-28.3) 24.2 (21.9-27.1) 23.7 (21.7-26.8) 
Primiparus, n(%) 38 (38.0) 298 (44.7) 295 (51.6) 318 (46.3) 
Smoker (in pregnancy), n(%) 23 (23.0) 138 (20.7) 63 (11.0) 86 (12.5) 
Educational attainment, n(%)      
None 4 (4.0) 29 (4.4) 9 (1.6) 15 (2.2) 
GCSE grade D or below 14 (14.0) 68 (10.2) 59 (10.3) 63 (9.2) 
GCSE grade C or above 30 (30.0) 188 (28.2) 170 (29.7) 192 (28.0) 
A-level or equivalent 33 (33.0) 206 (30.9) 167 (29.2) 213 (31.0) 
HND or equivalent 3 (3.0) 42 (6.3) 38 (6.6) 55 (8.0) 
Degree 16 (16.0) 133 (20.0) 129 (22.6) 149 (21.7) 
Total vitamin D intake in LP 2.9 (2.2-4.1) 3.5 (2.5-4.7) 3.6 (2.6-5.4) 4.5 (3.2-9.2) 
Use of vitamin D supplements in LP, n(%) 6 (1.4) 57 (13.0) 124 (28.3) 251 (57.3) 
Season of blood sampling, n (%) April-Sept 22 (22.0) 200 (30) 309 (54) 534 (77.7) 
White ethnicity, n (%) 79 (79.0) 624 (93.7) 563 (98.4) 675 (98.3) 
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Children      
Female, n(%) 48 (48.0) 357 (53.6) 298 (52.1) 353 (51.4) 
Birthweight, grams 3437 (503) 3444 (509) 3523 (510) 3501 (464) 
Gestational age, weeks 40 (39.0-40.8) 40.1 (39.1-41.0) 40.1 (39.3-41.1) 40.1 (39.1-41.0) 
Completed months of breastfeeding, n(%)      
Never tried 25 (25.0) 130 (19.5) 108 (18.9) 106 (15.4) 
<1 19 (19.0) 138 (20.7) 121 (21.2) 134 (19.5) 
1 to 3 17 (17.0) 157 (23.6) 111 (19.4) 143 (20.8) 
4 to 6 15 (15.0) 107 (16.1) 95 (16.6) 127 (18.5) 
7 to 11 15 (15.0) 91 (13.7) 95 (16.6) 106 (15.4) 
12+ 9 (9.0) 43 (6.5) 42 (7.3) 71 (10.3) 
 
 
 
 
 
